Raab & Moskowitz Asset Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.2% in the first quarter, Holdings Channel.com reports. The fund owned 5,136 shares of the biopharmaceutical company’s stock after buying an additional 253 shares during the quarter. Raab & Moskowitz Asset Management LLC’s holdings in Gilead Sciences were worth $331,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Barrett Asset Management LLC grew its holdings in Gilead Sciences by 333.0% during the 4th quarter. Barrett Asset Management LLC now owns 433 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 333 shares during the period. TFO TDC LLC acquired a new stake in Gilead Sciences during the 4th quarter worth $26,000. Tortoise Investment Management LLC grew its holdings in shares of Gilead Sciences by 81.6% in the 4th quarter. Tortoise Investment Management LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 200 shares during the period. Graves Light Private Wealth Management Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $27,000. Finally, Joseph P. Lucia & Associates LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. 76.36% of the stock is owned by hedge funds and other institutional investors.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 1,975 shares of the stock in a transaction that occurred on Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total transaction of $133,134.75. Following the transaction, the executive vice president now owns 28,832 shares in the company, valued at approximately $1,943,565.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 1,486 shares of the stock in a transaction that occurred on Thursday, March 11th. The stock was sold at an average price of $63.36, for a total transaction of $94,152.96. Following the transaction, the executive vice president now owns 29,166 shares in the company, valued at approximately $1,847,957.76. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.
GILD has been the subject of several research analyst reports. SVB Leerink boosted their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the company an “outperform” rating in a report on Friday. Guggenheim raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Monday, January 4th. TheStreet raised shares of Gilead Sciences from a “c” rating to a “b-” rating in a report on Tuesday, March 30th. Sanford C. Bernstein raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research report on Thursday, April 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday. Ten analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $98.21.
Shares of GILD stock traded up $0.46 on Tuesday, reaching $66.26. The stock had a trading volume of 213,503 shares, compared to its average volume of 8,324,578. The company has a quick ratio of 3.15, a current ratio of 3.25 and a debt-to-equity ratio of 1.65. The firm’s 50-day moving average is $65.14 and its two-hundred day moving average is $62.74. The firm has a market capitalization of $83.43 billion, a price-to-earnings ratio of 67.84, a P/E/G ratio of 0.67 and a beta of 0.51. Gilead Sciences, Inc. has a 12 month low of $56.56 and a 12 month high of $81.76.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.02. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 29th. Investors of record on Tuesday, June 15th will be paid a $0.71 dividend. The ex-dividend date is Monday, June 14th. This represents a $2.84 dividend on an annualized basis and a yield of 4.29%. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.25%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Further Reading: Bollinger Bands
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.